Molecular Pathology Unit

Our Mission

Our goal is to identify novel putative cancer targets for drug discovery, diagnostic and/or prognostic applications.
For this purpose, we use a high throughput screening technology (Tissue Microarrays, TMA) together with in situ detection methods (ISH and IHC) to rapid translate early discoveries into clinical application. TMA allows:

• Validation of basic research findings, based on rapid and simultaneous analysis of thousands of patient's tissues;
• Assessment of the prevalence of deregulation of target genes, based on comparative expression analysis between the tumor and the normal counterpart;
• Identification of new diagnostic and prognostic markers, based on correlation of expression results with clinico-pathological and follow-up data;
• Optimization of the drug discovery process, based on analysis at a cellular resolution level of human tissues samples representing the disease the drug is developed against.

Our Service

• Tissue banking
• Tissue microarrays manufacturing
• In situ analysis (RNA in situ hybridization, immunohistochemistry, FISH, etc)
• Laser Capture Microdissection (PALM System)
• Target validation
• Technical support
• Pathology expertise
• Clinical data correspondence
• Complete molecular report with image collection and data interpretation
• Statistical analysis
• Clinico-pathological and molecular databases